Time to rethink microscopic colitis? New study finds NO causative association between NSAIDs, PPIs, statins, or ACE inhibitors with microscopic colitis. 💊 #MedTwitter #GITwitter #IBD acpjournals.org/doi/10.7326/AN…

1/5 How reproducible are phase III oncology trials? 📊 With Alexander Sherry Erik van Zwet Ethan Ludmir MD et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. pubmed.ncbi.nlm.nih.gov/40628175/ 👇#MsaouelLab

📣 Calling resident doctors! Interested in an exciting and fast-moving career in Medical Oncology? Join us for a webinar on Mon July 14th @ 1800 BST Hear about MedOnc as a career and how to apply! Sign up here… us02web.zoom.us/webinar/regist… The Royal College of Radiologists Royal College of Psychiatrists JRCPTB

🧴 Prophylactic skincare (MD meds + pharmacist education + nurse-led care) in NSCLC pts on #Nivo + #Ipi ± chemo led to ↓ skin toxicities (21%➡8%), ↓ steroid use (36%➡10%), ↓ discontinuation (21%➡4%). 🔗 ascopubs.org/doi/10.1200/OP… OncoAlert #SupportiveCare #Immunotherapy

NEW PAPER in The BMJ "Dealing with continuous variables and modelling non-linear associations in healthcare data: practical guide" --> bmj.com/content/390/bm… #methodologymatters

📢Now in Pre-proof (JTO): Post-hoc IPSOS in NSCLC pts unsuitable for platinum-doublet chemo. 🟢89% met sPI criteria (Venn) 📈Atezolizumab improved OS vs chemo (HR 0.78), safety & QoL. Key data behind EMA approval, building on practice-changing IPSOS trial rb.gy/53nyez

In patients with atrial fibrillation, starting anticoagulation within 4 days after acute ischemic #stroke rather than later leads to fewer early recurrent strokes with no significant intracranial hemorrhage signal, a meta-analysis suggests. jwat.ch/4l6sdS8 #NeuroTwitter

Use of bronchial wash fluid for NGS testing in NSCLC reported JCO Precision Oncology. Concordance between bronchial wash and tissue was 94%. ctDNA from bronchial wash was more comparable to tissue than plasma in this study. ascopubs.org/doi/10.1200/PO…

🎉🎉🎉We celebrate #FDA approval of #zongertinib as the first TKI in #HER2-mutant #NSCLC 🎊 🎂 🌺 🩷 👉 ORR 71% 👉 Duration of Response 14.1 months 👉 PFS 12.4 months 👉 Well-tolerated at 120mg dose 📖 In previously treated patients without prior anti-HER2 targeted therapies

Incredibly exciting time for HER2 NSCLC, and an oral TKI with high ORR with no ILD! Not sure when we’ll get it in the UK though… we don’t even have access to T-DXd 🫣

📢 Our full IPSOS brief report is now published online in JTO & JTO CRR ✨📄 Phase III: post hoc validation of platinum-ineligible NSCLC pts 🫁 Free access for 50 days 🔗 bit.ly/4oDwCz0 Key analysis underpinning EMA approval & building on the practice-changing IPSOS trial

First-line MET TKI vs ICI ± Chemo in METex14-mutant NSCLC (n = 158, retrospective) OS/PFS➡️No overall difference 📌 PD-L1 ≥80%: ICI±chemo favored 📌 PD-L1 <50%: MET TKI 📌 Brain/bone mets: MET TKI 💬 Results suggest treatment benefit may vary across PD-L1 subgroups and